Mainstay Medical Holdings Plc: Business Overview, Financials & Competitive Analysis
Mainstay Medical Holdings Plc scores 7/10 on the AskCyborg Cyborg Score (Strong). FDA-approved restorative neurostimulation pioneer targeting a large, underserved chronic pain market with strong capital backing and growing international presence. Mainstay Medical has achieved FDA approval for its flagship product, secured substantial venture capital, and demonstrated clinical validation through five-year follow-up studies. However, the company remains private and early.
What is Mainstay Medical Holdings Plc's industry? Mainstay Medical Holdings Plc (mainstaymedical.com) operates in Neurostimulation Devices. AskCyborg classifies Mainstay Medical Holdings Plc under Neurostimulation Devices in its company registry.
Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions. ReActiv8® is the first and only FDA-approved restorative treatme...
Cyborg Score thesis
FDA-approved restorative neurostimulation pioneer targeting a large, underserved chronic pain market with strong capital backing...
Read the full analyst-debate transcript →Get the Latest Mainstay Medical Holdings Plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMainstay Medical Holdings Plc Overview
Pro stress-test →Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions. ReActiv8® is the first and only FDA-approved restorative treatment for mechanical chronic low back pain. The company targets an underserved patient population that has failed conventional pain management approaches.
Strategic Profile
Pro stress-test →The company secured a significant $125 million equity financing led by Gilde Healthcare (February 2024), indicating strong investor confidence and providing substantial resources to scale sales efforts and accelerate product adoption. With subsidiaries in Ireland, the US, Australia, Germany, and the Netherlands, and recent office expansions including the Dublin facility, Mainstay Medical is actively increasing its market presence and distribution channels across key regions.
Competitive Landscape
Pro stress-test →Mainstay Medical competes against established palliative pain management solutions including spinal cord stimulation (Medtronic, Boston Scientific), oral medications, interventional procedures (epidural injections, radiofrequency ablation), and physical therapy. Unlike these approaches, ReActiv8 uniquely offers a restorative mechanism targeting neuromuscular function rather than symptom suppression, creating a differentiated competitive position in the chronic low back pain market.
Industry Context
Mainstay Medical Holdings Plc operates in Neurostimulation Devices.
Key facts
Founded: 2008 · Headquarters: San Diego, US (Dublin, Ireland incorporation) · Employees: 162 (September 2025) · Revenue: $15M (September 2025)